A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

BACKGROUND: Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolum...

Descripción completa

Detalles Bibliográficos
Autores principales: Meindl-Beinker, Nadja M., Betge, Johannes, Gutting, Tobias, Burgermeister, Elke, Belle, Sebastian, Zhan, Tianzuo, Schulte, Nadine, Maenz, Martin, Ebert, Matthias P., Haertel, Nicolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419339/
https://www.ncbi.nlm.nih.gov/pubmed/30871493
http://dx.doi.org/10.1186/s12885-019-5446-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419339/
https://www.ncbi.nlm.nih.gov/pubmed/30871493
http://dx.doi.org/10.1186/s12885-019-5446-2

Ejemplares similares